Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides

被引:105
作者
Couvreur, P [1 ]
BlancoPrieto, MJ [1 ]
Puisieux, F [1 ]
Roques, B [1 ]
Fattal, E [1 ]
机构
[1] CNRS,URA D 1500,INSERM,U266,DEPT PHARMACOCHIM MOL & STRUCT,F-75270 PARIS 06,FRANCE
关键词
microspheres; multiple emulsion solvent evaporation technique; poly(lactic-co-glycolic acid); peptides V3 BRU; cholecystokinin; brain delivery; release kinetic;
D O I
10.1016/S0169-409X(97)00052-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper reviews the preparation and characterization of small poly(lactic-co-glycolic acid) microspheres (mean size lower than 10 mu m) containing small peptides and prepared by a water-in-oil-in-water emulsion solvent evaporation technique. These microspheres were shown to encapsulate very efficiently a 33 amino acid peptide (V3 BRU) and in vitro release kinetics studies showed that such microspheres could be employed for both oral vaccination and controlled release. The encapsulation of a seven amino acid peptide (pBC 264) led on the contrary to a very low encapsulation efficiency. In order to increase the encapsulation of pBC 264, two strategies were adopted: (i) taking into account the solubility of pBC 264 at different pH, the inner aqueous phase was maintained at a basic pH where the peptide was soluble, while the external aqueous phase was acidic; (ii) ovalbumin was added to stabilize the inner emulsion. These two strategies allowed us to increase significantly the encapsulation rate of pBC 264. Nevertheless, the in vitro release kinetics of the peptide were strongly influenced by the presence of ovalbumin which seems to form pores in the microsphere structure. By contrast, when ovalbumin was replaced by Pluronic(R) F68, microspheres did not have pores, thus the release profile and the extent of the burst were much smaller. When microspheres were stereotactically implanted in the rat brain, in vivo release profiles were in good agreement with the release observed in vitro. In conclusion, these microspheres are well suited for the slow delivery of neuropeptides in the brain, a feature expected to facilitate the study of long term effects of these compounds. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:85 / 96
页数:12
相关论文
共 62 条
  • [31] BIODEGRADABLE POLYMER SYSTEMS FOR THE SUSTAINED-RELEASE OF POLYPEPTIDES
    HUTCHINSON, FG
    FURR, BJA
    [J]. JOURNAL OF CONTROLLED RELEASE, 1990, 13 (2-3) : 279 - 294
  • [32] INFLUENCES OF CHOLECYSTOKININ AND ANALOGS ON MEMORY PROCESSES
    ITOH, S
    LAL, H
    [J]. DRUG DEVELOPMENT RESEARCH, 1990, 21 (04) : 257 - 276
  • [33] BIODEGRADABLE POLY(LACTIC ACID) AND POLY(LACTIDE-CO-GLYCOLIDE) MICROCAPSULES - PROBLEMS ASSOCIATED WITH PREPARATIVE TECHNIQUES AND RELEASE PROPERTIES
    JALIL, R
    NIXON, JR
    [J]. JOURNAL OF MICROENCAPSULATION, 1990, 7 (03) : 297 - 325
  • [34] PRINCIPAL NEUTRALIZING DOMAIN OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 ENVELOPE PROTEIN
    JAVAHERIAN, K
    LANGLOIS, AJ
    MCDANAL, C
    ROSS, KL
    ECKLER, LI
    JELLIS, CL
    PROFY, AT
    RUSCHE, JR
    BOLOGNESI, DP
    PUTNEY, SD
    MATTHEWS, TJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) : 6768 - 6772
  • [35] THE PREPARATION AND CHARACTERIZATION OF POLY(LACTIDE-CO-GLYCOLIDE) MICROPARTICLES .2. THE ENTRAPMENT OF A MODEL PROTEIN USING A (WATER-IN-OIL)-IN-WATER EMULSION SOLVENT EVAPORATION TECHNIQUE
    JEFFERY, H
    DAVIS, SS
    OHAGAN, DT
    [J]. PHARMACEUTICAL RESEARCH, 1993, 10 (03) : 362 - 368
  • [36] STABILITY OF ATRIOPEPTIN-III IN POLY(D,L-LACTIDE-CO-GLYCOLIDE) MICROSPHERES
    JOHNSON, RE
    LANASKI, LA
    GUPTA, V
    GRIFFIN, MJ
    GAUD, HT
    NEEDHAM, TE
    ZIA, H
    [J]. JOURNAL OF CONTROLLED RELEASE, 1991, 17 (01) : 61 - 67
  • [37] Jones E, 1996, PHARM TECHNOLOGY EUR, V8, P30
  • [38] KULKARNI R K, 1971, Journal of Biomedical Materials Research, V5, P169, DOI 10.1002/jbm.820050305
  • [39] NEW METHODS OF DRUG DELIVERY
    LANGER, R
    [J]. SCIENCE, 1990, 249 (4976) : 1527 - 1533
  • [40] LEE VHL, 1988, CRIT REV THER DRUG, V5, P69